Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.
Subtype terms (1)
More specific conditions that are subtypes of Chagas Disease in the MeSH hierarchy.
- Chagas Cardiomyopathy
9 drugs (8 approved, 1 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (4)
Phase 3 trials (1)
Phase 2 trials (6)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (9)
Organization Involved with Phase 3 Indications (17)
- Bayer
- Fundación Cardioinfantil Instituto de Cardiología
- Pan American Health Organization
- World Health Organization
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Instituto Dante Pazzanese de Cardiologia
- McMaster University
- Tulane University
- Universidad Autónoma de Bucaramanga
- University of California, San Diego
- University of Sao Paulo
- Fundacion Clinica Shaio, Bogota, Colombia
- Canadian Institutes of Health Research (CIHR)
- National Council of Scientific and Technical Research, Argentina
- Instituto Nacional de Salud (Colombia)
- Government of Brazil
- Insud Pharma
Organization Involved with Phase 2 Indications (12)
- Eisai
- Merck
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Institute of Allergy and Infectious Diseases (NIAID)
- Food and Drug Administration
- Universidad Mayor San Simón, Cochabamba, Bolivia.
- Centre de Recerca en Salut Internacional de Barcelona, Spain.
- Universidad Autonoma de Barcelona
- University of Texas, El Paso
- Mundo Sano Foundation
- Institute of Parasitology and Biomedicine Lopez Neyra
- Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (6)